Akero Therapeutics Inc (AKRO)
31.20
+0.56
(+1.84%)
USD |
NASDAQ |
Nov 21, 16:00
31.22
+0.02
(+0.06%)
After-Hours: 20:00
Akero Therapeutics Enterprise Value: 1.496B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 1.496B |
| November 20, 2024 | 1.456B |
| November 19, 2024 | 1.484B |
| November 18, 2024 | 1.381B |
| November 15, 2024 | 1.279B |
| November 14, 2024 | 1.395B |
| November 13, 2024 | 1.480B |
| November 12, 2024 | 1.578B |
| November 11, 2024 | 1.624B |
| November 08, 2024 | 1.722B |
| November 07, 2024 | 1.752B |
| November 06, 2024 | 1.780B |
| November 05, 2024 | 1.603B |
| November 04, 2024 | 1.555B |
| November 01, 2024 | 1.574B |
| October 31, 2024 | 1.470B |
| October 30, 2024 | 1.455B |
| October 29, 2024 | 1.527B |
| October 28, 2024 | 1.386B |
| October 25, 2024 | 1.360B |
| October 24, 2024 | 1.319B |
| October 23, 2024 | 1.314B |
| October 22, 2024 | 1.378B |
| October 21, 2024 | 1.469B |
| October 18, 2024 | 1.492B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.463B |
| October 16, 2024 | 1.479B |
| October 15, 2024 | 1.401B |
| October 14, 2024 | 1.407B |
| October 11, 2024 | 1.381B |
| October 10, 2024 | 1.342B |
| October 09, 2024 | 1.303B |
| October 08, 2024 | 1.278B |
| October 07, 2024 | 1.180B |
| October 04, 2024 | 1.284B |
| October 03, 2024 | 1.243B |
| October 02, 2024 | 1.351B |
| October 01, 2024 | 1.325B |
| September 30, 2024 | 1.315B |
| September 27, 2024 | 1.235B |
| September 26, 2024 | 1.312B |
| September 25, 2024 | 1.219B |
| September 24, 2024 | 1.222B |
| September 23, 2024 | 1.245B |
| September 20, 2024 | 1.224B |
| September 19, 2024 | 1.219B |
| September 18, 2024 | 1.147B |
| September 17, 2024 | 1.124B |
| September 16, 2024 | 1.133B |
| September 13, 2024 | 1.173B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
103.76M
Minimum
Oct 27 2023
2.828B
Maximum
Jun 13 2023
903.30M
Average
702.61M
Median
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals Inc | 6.299B |
| 89bio Inc | 597.11M |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -72.70M |
| Total Expenses (Quarterly) | 81.70M |
| EPS Diluted (Quarterly) | -1.05 |
| Earnings Yield | -12.12% |